Furthermore, in vivo findings from mouse xenografts indicated the essential role of COL11A1 in tumor progression and CAF activation, and that anti-TGF-β3 therapy could inhibit tumor growth and reverse CAF activation. This evidence concerns the gene COL11A1 and neoplasm.